Шаблоны LeoTheme для Joomla.
GavickPro Joomla шаблоны

diabetes banner

Editorial

Lifestyle Modification Program, KOHNODAI Program

Hidekatsu Yanai1*, Hisayuki Katsuyama1, Akiko Kawaguchi1, Sumie Moriyama1, Hidetaka Hamasaki1, Hiroshi Ohkubo1, Keiko
Osako1, and Airi Sanada1

1Department of Internal Medicine, National Center for Global Health and Medicine Kohnodai Hospital, Chiba, Japan

*Corresponding author: Dr. Hidekatsu Yanai, M.D., Ph.D., F.A.C.P. Department of Internal Medicine, National Center for Global Health and Medicine Kohnodai Hospital, 1-7-1 Kohnodai, Chiba, Japan, Tel: 272-8516;
E-mail: dyanai@hospk.ncgm.go.jp

Submitted: 07-02-2014 Accepted: 07-03-2014  Published: 07-04-2014

Download PDF

_________________________________________________________________________________________________________________________

 

Article

 

Obesity is known to be associated with metabolic disorders, such as glucose intolerance, hypertension and dyslipidemia. Especially, metabolic abnormalities in obesity have been shown to be frequently associated with abdominal obesity [1-7]. In Japan, the number of metabolic disorders was greater than 1.0 at 100cm2 of visceral fat area (VFA)and the best combination of the sensitivity and specificity for determining subjects with multiple risk factors was 100 cm2 of VFA [8]. The regression line obtained from simple correlation analyses indicated that the waist circumference corresponding to 100cm2 of VFA was 84.4 cm in men and 92.5cm in women [8]. Therefore, a waist circumference (≧90cm for women and ≧85cm for men) is defined as abdominal obesity in the Japanese diagnostic criteria for metabolic syndrome [8].

Our hospital, Kohnodai Hospital belongs to National Center for Global Health and Medicine (NCGM), Japan. The mission of NCGM is to provide the best general healthcare services to overcome diseases and improve health with the aim of contributing to society. Prevention of obesity-related metabolic abnormalities such as type 2 diabetes and the metabolic syndrome is an important mission for NCGM. Therefore, we created the program to support obese patients to change their lifestyle related with obesity, and named this program KOhnodai Hospital NCGM Obesity-related Diet and Physical Activity Improvement (KOHNODAI) program.

The summary of KOHNODAI program was shown in Table 1. This program is scheduled to be completed for 5 days, and start on Friday and finish on next Tuesday for a busy businessman. On Day 1, we perform a medical check-up tounderstand that obese patients can take diet therapy and exercise safely. We measure the markers of atherosclerosis, and also visceral and subcutaneous fat, which can motivate patients to participate actively in this program.Physical therapists make an individual exercise program which depends on age, exercise capacity and endurance, cardiopulmonary function of each patient, and instructed patients to do exercise. Our diet therapy includes the small restriction of calorie intake [25 kcal/kg (ideal body weight) /day]. On Day 2 and Day 3, patients take diet therapy and exercise. On Day 4, we measure serum levels of aspartate aminotransferase, alanine aminotransferase, triglyceride, low-density lipoprotein-cholesterol and high-density lipoprotein-cholesterol, and fasting plasma glucose and HbA1c, to understand whether patients have non-alcoholic fatty liver diseases (NAFLD), dyslipidemia, the metabolic syndrome, impaired glucose tolerance and type 2 diabetes, or not. We also measure basal metabolic rate which influence on changes in body weight. In the afternoon of Day 4, patients receive the instruction of nutrition therapy by the registered dietitians individually. The contents of teaching depend on diseases which each patient have such as type 2 diabetes and hypertension. On Day 5, each patient reflects on KOHNODAI program and their lifestyle.

The KOHNODAI program has two characteristic contents. First, the patients measure and record body weight four times a day by themselves on Days 1-5, which make patients discover what increase or decrease their body weight, and how their body weight change. Secondly, patients and nurses discuss on their lifestyle for one hour on Days 1-5. Nurses make patients discover their problems and remedy, and encourage patients to modify their lifestyle.

We will mention the advantages of our program. First, the severity and complication (NAFLD, atherosclerosis, metabolic disorders) of obesity in patients can be evaluated within 5 days. Secondly, obese patients can learn diet therapy and exercise to lose body weight within 5 days. Thirdly, obese patients can discover their lifestyle related withobesity by themselves. Twenty nine obese patients with severe visceral obesity completed the KOHNODAI program. Most of participated patients lost body weight. We will report a full detail of effects of KOHNODAI program on metabolic parameters in the future.

Acknowledgements

This work was supported by a grant from the National Center for Global Health and Medicine (25-203).

Conflict of Interests

The authors declare that they have no competing interests.
 

References

 References

1.Fishman GA, Birch DG, Holder GE, Brigell MG. Electrophysiologic Testing in Disorders of the Retina, Optic Nerve and Visual Pathway. 2nd ed. Singapore: LEO. The Foundation of the American Academy of Ophthalmology, San Francisco. 2001.

2.Papanas N, Paschos P, Papazoglou D, Papatheodorou K, Paletas K et al. Accuracy of the Neuropad test for the diagnosis of distal symmetric polyneuropathy in type 2 diabetes. Diabetes Care. 2011, 34: 1378-382.

3.Nebbioso M, D’Innocenzo D, Rapone S, Di Benedetto G, Grenga R. Nystagmus in Ophthalmology. Clin Ter. 2009, 2: 145-149.

4.Nebbioso M, Lenarduzzi F, Pucci B, Platerori AM, Rispoli E. Surgical management by means of electroretinographic examination during Extracorporeal Circulation. Ann Ital Chir. 2011, 83: 523-528.

5.Nebbioso M, Di Benedetto G, Grenga R. Inherited macular Pattern dystrophies: a case report, diagnostic methodology, state of the art. Clin Ter. 2008, 6: 427-430.

6.Nebbioso M, Livani ML, Vingolo EM, Belcaro G, Pecorella I. Coats’-type changes in a retinitis pigmentosa family. Panminerva Med. 2014, 56(S2): 15-18.

7.Malagola R, Arrico L, Belcaro G, Lenarduzzi F, Nebbioso M. Retinal electrofunctional alterations in patients affected by juvenile diabetes. Panminerva Med 2014, 56(S2): 19-21.

8.Vingolo EM, Gerace E, Valente S, Spadea L, Nebbioso M. Microincision vitrectomy surgery in vitreomacular traction syndrome of retinitis pigmentosa patients. BioMed Research International. 2014, 537081: 1-7.

9.Nebbioso M, De Gregorio F, Prencipe L, Pecorella I. Psychophysical and electrophysiological testing in ocular hypertension. Optom Vis Sci. 2011, 88: E928-E939.

10.Sutter EE, Tran D. The field topography of ERG components in man. The photopic luminance response. Vision Res. 1992, 32: 433-466.

11.Marmor MF, Hood DC, Keating D, Kondo M, Seeliger MW et al. Guidelines for basic multifocal electroretinography (mfERG). Doc Ophthalmol. 2003, 106: 105-115.

12.Hood DC, Bach M, Brigell M, Keating D, Kondo M et al. ISCEV guidelines for clinical multifocal electroretinography (2007 ed). Doc Ophthalmol. 2008, 116: 1-11.

13.Nebbioso M, Livani ML, Steigerwalt RD, Panetta V, Rispoli E. Retina in rheumatic diseases: Standard full field and multifocal electroretinography in hydroxychloroquine retinal dysfunction. Clin Exp Optom. 2010, 94: 276-283.

14.Nebbioso M, Grenga R, Karavitis P. Early detection of macular changes with multifocal ERG in patients on antimalarial drug therapy. J Ocul Pharmacol Ther. 2009, 3: 249- 258.

15.Hood DC, Frishman LJ, Saszik S, Viswanathan S. Retinal origins of the primate multifocal ERG: implications for the human response. Inv Ophthalmol Vis Sci. 2002, 43: 1673- 1685.

Cite this article: Yanai. H Lifestyle Modification Program, KOHNODAI Program. J J Diab Endocrin. 2014, 1(1): 004.

 

Contact Us:
9600 GREAT HILLS
TRAIL # 150 W
AUSTIN, TEXAS
78759 ( TRAVIS COUNTY)
E-mail : info@jacobspublishers.com
Phone : 512-400-0398